Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
NASDAQ:EVAX
Price:
4.03
USD
-5.18%
Market Closed
Market Cap:
$33.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Evaxion Biotech A/S
Change in Working Capital
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Evaxion Biotech A/S
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Change in Working Capital
$1.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Change in Working Capital
-kr110m
|
CAGR 3-Years
38%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-4%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Change in Working Capital
-kr730.6m
|
CAGR 3-Years
-325%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Change in Working Capital
-$2.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Change in Working Capital
-€20.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-234%
|
CAGR 10-Years
-18%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Change in Working Capital
kr95.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
12%
|
|
No Stocks Found
Evaxion Biotech A/S
Glance View
Evaxion Biotech A/S discovers and develops novel immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
EVAX
Intrinsic Value
Not Available
See Also
What is Evaxion Biotech A/S's Change in Working Capital?
Change in Working Capital
1.7m
USD
1.7m
USD
Based on the financial report for Dec 31, 2025, Evaxion Biotech A/S's Change in Working Capital amounts to 1.7m USD.
What is Evaxion Biotech A/S's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
11%
11%
Over the last year, the Change in Working Capital growth was 264%.
